SCHEMBL3602790

SCHEMBL3602790

O=C(O)N1CCC(CO)(c2ccc(F)c(F)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.43
SLC6A3 Q01959 3/20 0.43
PRKAB2 O43741 5/20 0.42
PRKAG1 P54619 5/20 0.42
PRKAA2 P54646 5/20 0.42
PRKAA1 Q13131 5/20 0.42
PRKAG3 Q9UGI9 5/20 0.42
PRKAG2 Q9UGJ0 5/20 0.42
PRKAB1 Q9Y478 5/20 0.42
SLC6A2 P23975 2/20 0.40
HSD11B1 P28845 1/20 0.40
CCR2 P41597 1/20 0.39
DRD2 P14416 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TACR1 P25103 1/20 0.35
MCHR1 Q99705 1/20 0.35
APP P05067 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425390 0.84 HSD11B1 (0.49) SLC6A3HSD11B1DRD2
SCHEMBL13404311 0.81 TACR1 (0.48) HSD11B1TACR1
SCHEMBL3384526 0.81 DRD2 (0.45) DRD2MEN1KMT2A
SCHEMBL5169875 0.79 SLC6A4 (0.39) SLC6A4SLC6A3SLC6A2CCR2DRD2
SCHEMBL3588034 0.79 TACR1 (0.45) SLC6A4SLC6A3SLC6A2HSD11B1CCR2
SCHEMBL2425376 0.79 HSD11B1 (0.58) HSD11B1MEN1KMT2ATACR1CYP2D6
SCHEMBL3585852 0.78 HSD11B1 (0.45) HSD11B1MEN1KMT2ATACR1
SCHEMBL21680273 0.78 SLC6A3 (0.45) SLC6A4SLC6A3PRKAB2PRKAG1PRKAA2
SCHEMBL28123227 0.77 TACR1 (0.44) SLC6A4SLC6A3SLC6A2HSD11B1MEN1
SCHEMBL28077549 0.77 HSD11B1 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383821-B2 NK-1 and serotonin transporter inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-08 US disclosed
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors SLC6A4, TPH1, SLC6A2 SLC6A4 1/4885SLC6A3 6/4885PRKAB2 1642/4885
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS SLC6A4, TPH1, SLC6A2 SLC6A4 1/4885SLC6A3 6/4885PRKAB2 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.